shortness of breath; fever; chills; hot & cold; aching joints; dizzy & light headed, almost fainted; pounding headaches; no energy, weakness; sore throat; congestion/ congestion nasal; loss of smell; this is a spontaneous report received from a contactable reporter (consumer) from a regulatory authority. the reporter is the patient. other case identifiers: gb-mhra-vac-202202141650427980-x2vak and gb-mhra-adr 26602671. a 56-year-old female patient received bnt162b2 (comirnaty), administration date 27jan2022 (batch/lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: covid-19 vaccine (primary immunization series complete; unknown manufacturer), for covid-19 immunisation. the following information was reported: dyspnoea (medically significant) with onset 28jan2022, outcome "not recovered", described as "shortness of breath"; pyrexia (medically significant) with onset 28jan2022, outcome "not recovered", described as "fever"; chills (medically significant) with onset 28jan2022, outcome "not recovered", described as "chills"; feeling of body temperature change (medically significant) with onset 28jan2022, outcome "not recovered", described as "hot & cold"; arthralgia (medically significant) with onset 28jan2022, outcome "not recovered", described as "aching joints"; dizziness (medically significant) with onset 28jan2022, outcome "not recovered", described as "dizzy & light headed, almost fainted"; headache (medically significant) with onset 28jan2022, outcome "not recovered", described as "pounding headaches"; asthenia (medically significant) with onset 28jan2022, outcome "not recovered", described as "no energy, weakness"; oropharyngeal pain (medically significant) with onset 28jan2022, outcome "not recovered", described as "sore throat"; nasal congestion (medically significant) with onset 28jan2022, outcome "not recovered", described as "congestion/ congestion nasal"; and anosmia (medically significant) with onset 28jan2022, outcome "not recovered", described as "loss of smell." clinical course: once the patient received the covid vaccine booster, the following day, the side-effects became full-blown and "lasted beyond 3 weeks" (as reported). she contacted her gp who advised her to remain at home and declared her unfit for work. blood test, blood pressure, and chest x-ray appointments were also organized for her. the medicine was obtained from a covid walk-in medical centre. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected